Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer

Conditions:   Borderline Ovarian Mucinous Tumor;   Ovarian Mucinous Cystadenocarcinoma;   Recurrent Fallopian Tube Carcinoma;   Recurrent Ovarian Carcinoma;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian CancerInterventions:   Biological: Bevacizumab;   Drug: Capecitabine;   Drug: Carboplatin;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Drug: Paclitaxel;   Other: Quality-of-Life AssessmentSponsor:   National Cancer Institute (NCI)Active, not recruiting - verified May 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials